72. (Once amended) A method of transferring a gene into [an animal] a recipient subject, comprising:

(a) transfecting somatic cells *in vitro* with a DNA sequence and without using a viral vector to introduce the DNA into the cells, wherein the DNA sequence comprises no DNA of retroviral origin, wherein the DNA sequence comprises the gene and a promoter operably linked to the gene;

(b) screening the resulting transfected somatic cells *in vitro* to select a cell possessing desired expression properties;

(c) cloning and expanding the selected somatic cell *in vitro*; and

(d) administering the resulting cloned and expanded somatic cells to the recipient subject [animal].

78. (Once amended) The method of claim 73, wherein the transfection [involves] comprises calcium phosphate-mediated transfection, microinjection, electroporation, or DEAE-dextran transfection.

79. (Once amended) The method of claim 73, wherein the transfected cells were originally obtained from an animal of the same species as that of the recipient subject [animal].

84. (Once amended) The method of claim 73, wherein the screening step further [involves] comprises screening the resulting transfected somatic cells *in vitro* to select a cell possessing desired [regulation] expression properties.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

85. (Once amended) The method of claim 73, wherein the screening step further [involves] comprises screening the resulting transfected somatic cells *in vitro* to select a cell free from a deleterious integration event.

86. (Once amended) The method of claim 73, wherein the DNA sequence cannot recombine with an endogenous retrovirus in the genome of the [animal] recipient subject.

87. (Once amended) A method of transferring a gene into [an animal] a recipient subject, comprising:

(a) transfecting somatic cells *in vitro* with a DNA sequence and without using a retroviral vector to introduce the DNA into the cells, wherein the sequence comprises no DNA of retroviral origin, wherein the DNA sequence comprises the gene and a promoter operably linked to the gene;

(b) screening the resulting transfected somatic cells *in vitro* to select a cell possessing desired expression properties;

(c) cloning and expanding the selected somatic cell *in vitro*; and

(d) administering the resulting cloned and expanded somatic cells to the recipient subject [animal].

93. (Once amended) The method of claim 88, wherein the transfection [involves] comprises calcium phosphate-mediated transfection, microinjection, electroporation, or DEAE-dextran transfection.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

94. (Once amended) The method of claim 88, wherein the transfected cells were originally obtained from an animal of the same species as that of the recipient subject [animal].

99. (Once amended) The method of claim 88, wherein the screening step further [involves] comprises screening the resulting transfected somatic cells *in vitro* to select a cell possessing desired [regulation] expression properties.

100. (Once amended) The method of claim 88, wherein the screening step further [involves] comprises screening the resulting transfected somatic cells *in vitro* to select a cell free from a deleterious integration event.

Please add new claims 102-103 as follows:

--102. A method of transferring a gene into a recipient subject, comprising:

(a) introducing a DNA sequence into somatic cells *in vitro* without using viral infection to introduce the DNA into the cells, wherein the DNA sequence comprises no DNA of retroviral origin, wherein the DNA sequence comprises the gene and a promoter operably linked to the gene;

(b) screening the somatic cells *in vitro* to select a cell possessing desired expression properties;

(c) cloning and expanding the selected somatic cell *in vitro*; and

(d) administering the resulting cloned and expanded somatic cells to the recipient subject.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

103. A method of transferring a gene into a recipient subject, comprising:

(a) introducing a DNA sequence into somatic cells *in vitro* without using retroviral infection to introduce the DNA into the cells, wherein the DNA sequence comprises no DNA of retroviral origin, wherein the DNA sequence comprises the gene and a promoter operably linked to the gene;

(b) screening the somatic cells *in vitro* to select a cell possessing desired expression properties;

(c) cloning and expanding the selected somatic cell *in vitro*; and

(d) administering the resulting cloned and expanded somatic cells to the recipient subject.--

REMARKS

Applicant has canceled claims 81 and 96, amended claims 72, 78, 79, 84-87, 93-94, and 99-100, and added new claims 102-103. The specification and original claims support the amendments to claims 72, 78, 79, 84-87, 93-94, and 99-100 and new claims 102-103. For example, the specification supports the recitation of "without using viral infection" and "without using retroviral infection" at , *inter alia*, page 4, lines 5-9; page 5, lines 8-10; and page 6, lines 28-31.

Upon entry of this amendment, claims 72-80, 82-95, and 97-103 will be pending in this application.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000